IL6 and depressive symptom measurement: Although IL‐6 also plays a key role in depression pathology, IL‐6‐targeted approaches (e.g., tocilizumab for residual depression) show inconsistent results and may even worsen mood in some patients, underscoring the need for precision therapy based on immune profiles [695].